VolitionRx Limited income statement VNRX

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, VolitionRx Limited reported revenue of $1.7 million, up 40.0% from the year before. It recorded a net loss of $23.4 million. The operating loss came to $21.7 million, an operating margin of -1258.5%. Over the twelve months ended Jun 30, 2026, revenue was $2.5 million and the net loss was $25.6 million. Across the 7 fiscal years shown, revenue grew from $17,096 in fiscal 2019 to $1.7 million in fiscal 2025, about 115.8% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	2 +86.3%	2 +40.0%	1 +59.1%	1 +153.0%	0 +240.3%	0 +570.3%	0 -21.4%	0	—	—	—
Research and development	9 -17.4%	10 -30.0%	14 -26.3%	20 +27.5%	15 +17.7%	13 -10.4%	15 +40.2%	10 -5.0%	11 +35.9%	8 +1.5%	8 +29.6%
Selling, general and administrative	12 -6.7%	13 -3.4%	14 -19.5%	17 +2.7%	17 +8.8%	15 +128.9%	7 +18.1%	6 -18.5%	7 +4.8%	7 +59.7%	4 +524.4%
Operating income	-19 +17.1%	-22 +19.6%	-27 +24.9%	-36 -13.2%	-32 -12.2%	-28 -33.3%	-21 -32.4%	-16 +10.4%	-18 -21.8%	-15 -18.2%	-12 -24.2%
Net income	-26 -9.9%	-23 +13.4%	-27 +24.4%	-36 -16.6%	-31 -13.4%	-27 -32.3%	-20 -26.7%	-16 +10.6%	-18 -21.9%	-15 -24.1%	-12 -24.9%
Diluted EPS	-0.24	—	-0.31	—	—	—	—	—	—	—	—
Weighted average shares, diluted	108	107 +23.5%	87	—	—	—	—	—	—	—	—
Other measures
Depreciation and amortization	1 -19.4%	1 -11.6%	1 -3.4%	1 +23.1%	1 -1.0%	1 +32.0%	1 +5.8%	1 +6.4%	1 +20.5%	1 +70.7%	0 +30.9%
EBITDA	-19 +17.0%	-21 +19.9%	-26 +25.6%	-35 -12.9%	-31 -12.6%	-27 -33.4%	-21 -33.6%	-15 +11.0%	-17 -21.8%	-14 -16.9%	-12 -24.1%
Interest coverage	—	—	—	—	—	-181.85x	-163.70x	-126.75x	—	-200.95x	—
Margins
Operating margin	-791.16%	-1,258.47%	-2,190.90%	-4,641.76%	-10,372.36%	-31,468.96%	-158,176.25%	-93,840.22%	—	—	—
Profit margin	-1,043.11%	-1,352.16%	-2,186.27%	-4,601.70%	-9,986.71%	-29,976.99%	-151,859.55%	-94,168.55%	—	—	—
EBITDA margin	-755.58%	-1,201.52%	-2,100.65%	-4,493.11%	-10,066.84%	-30,418.96%	-152,844.74%	-89,881.31%	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: VNRX (NYSE)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Henderson, NV
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 93314
Former names: VOLITIONRX LTD (until Oct 27, 2026); STANDARD CAPITAL CORP (until Sep 29, 2011)

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.